ストックスクリーナーアプリを入手
14.99
6.24%
0.88
アフターアワーズ：
15.11
0.12
+0.80%
前日終値:
$14.11
開ける：
$14.25
24時間の取引高:
5.08M
Relative Volume:
2.48
時価総額：
$1.75B
収益：
$59.61M
当期純損益:
$-262.14M
株価収益率:
-2.7058
EPS:
-5.54
ネットキャッシュフロー:
$-247.49M
1週間 パフォーマンス:
+18.12%
1か月 パフォーマンス:
+47.25%
6か月 パフォーマンス:
+81.04%
1年 パフォーマンス:
+478.76%
1日の値動き範囲:
$14.18
$15.79
1週間の範囲:
$12.63
$15.79
52週間の値動き範囲:
$2.51
$15.79
Arcutis Biotherapeutics Inc Stock (ARQT) Company Profile
名前
Arcutis Biotherapeutics Inc
セクター
電話
805-418-5006
住所
3027 TOWNSGATE ROAD, WESTLAKE VILLAGE, CA
ARQT を他の銘柄と比較する
| 株式 | 価格 | 時価総額 | 収益 | 当期純利益 | 現金流量 | EPS |
|---|---|---|---|---|---|---|
ARQT
Arcutis Biotherapeutics Inc
|
14.99 | 1.75B | 59.61M | -262.14M | -247.49M | -3.92 |
|
VRTX
Vertex Pharmaceuticals Inc
|
397.27 | 102.31B | 10.63B | -479.80M | -1.35B | -1.99 |
|
REGN
Regeneron Pharmaceuticals Inc
|
701.85 | 77.13B | 13.85B | 4.65B | 3.32B | 40.41 |
|
ARGX
Argen X Se Adr
|
623.82 | 37.30B | 1.86B | -40.29M | -1.28B | -0.85 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
245.44 | 31.66B | 2.09B | -332.26M | 16.06M | -2.62 |
|
BNTX
Biontech Se Adr
|
113.08 | 27.11B | 3.30B | -501.07M | 1.03B | -2.1146 |
Arcutis Biotherapeutics Inc Stock (ARQT) Upgrades & Downgrades
| 日付 | アクション | アナリスト | 評価の変更 |
|---|---|---|---|
| 2024-08-28 | 開始されました | Jefferies | Buy |
| 2024-01-03 | アップグレード | Mizuho | Neutral → Buy |
| 2023-10-26 | ダウングレード | Mizuho | Buy → Neutral |
| 2023-10-13 | ダウングレード | Goldman | Buy → Neutral |
| 2022-09-07 | 開始されました | Needham | Buy |
| 2022-03-17 | 開始されました | Goldman | Buy |
| 2021-06-30 | 開始されました | Mizuho | Buy |
| 2021-05-27 | アップグレード | Morgan Stanley | Equal-Weight → Overweight |
| 2020-11-09 | アップグレード | Goldman | Neutral → Buy |
| 2020-10-08 | 開始されました | Truist | Buy |
| 2020-02-25 | 開始されました | Cantor Fitzgerald | Overweight |
| 2020-02-25 | 開始されました | Cowen | Outperform |
| 2020-02-25 | 開始されました | Goldman | Neutral |
| 2020-02-25 | 開始されました | Guggenheim | Buy |
すべてを表示
Arcutis Biotherapeutics Inc (ARQT) 最新ニュース
Arcutis Biotherapeutics (NASDAQ:ARQT) Shares Up 4.2%Time to Buy? - MarketBeat
State Street Corp Boosts Stock Holdings in Arcutis Biotherapeutics, Inc. (NASDAQ:ARQT) - MarketBeat
Long Term Trading Analysis for (ARQT) - Stock Traders Daily
Arcutis Biotherapeutics (NASDAQ:ARQT) Stock Price Down 9.4%What's Next? - MarketBeat
Franklin Resources Inc. Decreases Stock Position in Arcutis Biotherapeutics, Inc. (NASDAQ:ARQT) - MarketBeat
Arcutis Biotherapeutics Soars on Zoryve Success and Bullish Analyst Ratings - Nasdaq
Investors Purchase Large Volume of Call Options on Arcutis Biotherapeutics (NASDAQ:ARQT) - MarketBeat
Arcutis stock soars to 52-week high, hits $13.56 amid robust gains - Investing.com Canada
Arcutis Biotherapeutics (NASDAQ:ARQT) Hits New 52-Week HighHere's Why - MarketBeat
FDA Receives sNDA for Roflumilast Cream Treatment of Children with Atopic Dermatitis - MD Magazine
Arcutis Biotherapeutics, Inc. (NASDAQ:ARQT) Sees Large Decrease in Short Interest - MarketBeat
Arcutis Submits ZORYVE® (roflumilast) Cream 0.05% Supplemental New Drug Application to the FDA for the Treatment of Children Aged 2 to 5 with Mild to Moderate Atopic Dermatitis - The Manila Times
Arcutis Submits FDA Application for ZORYVE Cream After Promising Child Eczema Trial Results - StockTitan
Arcutis stock soars to 52-week high, hits $13.56 amid robust gains By Investing.com - Investing.com South Africa
Arcutis Biotherapeutics (NASDAQ:ARQT) Trading Up 4.8%Here's Why - MarketBeat
Point72 Asset Management L.P. Invests $2.27 Million in Arcutis Biotherapeutics, Inc. (NASDAQ:ARQT) - MarketBeat
Arcutis Biotherapeutics, Inc. (NASDAQ:ARQT) Position Lessened by Jacobs Levy Equity Management Inc. - MarketBeat
How to Take Advantage of moves in (ARQT) - Stock Traders Daily
Arcutis Biotherapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) - The Manila Times
High Growth Tech Stocks To Watch In December 2024 - Simply Wall St
Arcutis Biotherapeutics Awards Equity Grants to New Employees Under Inducement Plan - StockTitan
Arcutis Biotherapeutics CEO Todd Watanabe buys $21,250 in stock - Investing.com India
Arcutis announces key executive promotions By Investing.com - Investing.com South Africa
Arcutis announces key executive promotions - Investing.com India
Wall Street Analysts See a 70.33% Upside in Arcutis Biotherapeutics (ARQT): Can the Stock Really Move This High? - MSN
Insider Sell Alert: Howard Welgus Sells 10,000 Shares of Arcutis Biotherapeutics Inc (ARQT) - GuruFocus.com
Arcutis Biotherapeutics director sells $125,132 in stock - Investing.com India
Arcutis Biotherapeutics CEO Todd Watanabe buys $21,250 in stock By Investing.com - Investing.com Canada
Arcutis Biotherapeutics director sells $125,132 in stock By Investing.com - Investing.com Nigeria
Arcutis Biotherapeutics exec buys $7,766 in stock By Investing.com - Investing.com Nigeria
Arcutis Biotherapeutics exec buys $7,766 in stock - Investing.com
Arcutis Announces Promotions on Executive Management Team - The Manila Times
Arcutis Biotherapeutics Strengthens Leadership Team Following ZORYVE Portfolio Success - StockTitan
Short Interest in Arcutis Biotherapeutics, Inc. (NASDAQ:ARQT) Drops By 9.9% - MarketBeat
Algert Global LLC Increases Stock Position in Arcutis Biotherapeutics, Inc. (NASDAQ:ARQT) - MarketBeat
Arcutis Biotherapeutics Submits Roflumilast Cream 0.15% Supplemental NDA to US FDA for Eczema Treatment - Marketscreener.com
Arcutis Biotherapeutics, Inc. (NASDAQ:ARQT) Stock Position Lifted by Suvretta Capital Management LLC - MarketBeat
Does Arcutis Biotherapeutics (ARQT) Have the Potential to Rally 60.12% as Wall Street Analysts Expect? - MSN
(ARQT) Investment Analysis - Stock Traders Daily
Arcutis Biotherapeutics, Inc. (ARQT) Now Trades Above Golden Cross: Time to Buy? - Zacks Investment Research
Rubric Capital Management LP Grows Holdings in Arcutis Biotherapeutics, Inc. (NASDAQ:ARQT) - MarketBeat
There's Reason For Concern Over Arcutis Biotherapeutics, Inc.'s (NASDAQ:ARQT) Massive 32% Price Jump - Simply Wall St
Arcutis Biotherapeutics, Inc. (NASDAQ:ARQT) Stock Position Increased by Jennison Associates LLC - MarketBeat
Arcutis Biotherapeutics, Inc. (ARQT) Recently Broke Out Above the 20-Day Moving Average - MSN
Bears are Losing Control Over Arcutis Biotherapeutics (ARQT), Here's Why It's a 'Buy' Now - MSN
Arcutis Biotherapeutics SVP sells $17,190 in stock By Investing.com - Investing.com Nigeria
Arcutis Biotherapeutics SVP sells $17,190 in stock - Investing.com India
Arcutis Biotherapeutics, Inc. (ARQT) Recently Broke Out Above the 200-Day Moving Average - Yahoo Finance
Arcutis Biotherapeutics, Inc. (ARQT) Crossed Above the 50-Day Moving Average: What That Means for Investors - Yahoo Finance
Arcutis Biotherapeutics, Inc. (ARQT) Reports Q3 Loss, Tops Revenue Estimates - MSN
Arcutis Biotherapeutics Inc (ARQT) 財務データ
収益
当期純利益
現金流量
EPS
2.88%
2.65%
大文字化:
|
ボリューム (24 時間):